Current and Resolved Drug Shortages and Discontinuations Reported to FDA
Report a Drug Shortage |
FAQ |
Background Info |
Get Email Alerts |
Download Current Drug Shortages |
Contact Us
Start Over | Back to Previous Screen
Carboplatin Injection
Status: Currently in Shortage
»Date first posted:
04/28/2023
»Therapeutic Categories: Oncology
Accord Healthcare Inc. (Revised 03/11/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Injection, 10 mg/1 mL (NDC 16729-295-34) | Unavailable, 30 days | Inventory on hold pending further assessment. | Requirements related to complying with good manufacturing practices |
| Injection, 10 mg/1 mL (NDC 16729-295-12) | Unavailable, 30 days | Inventory on hold pending further assessment. | Requirements related to complying with good manufacturing practices |
| Injection, 10 mg/1 mL (NDC 16729-295-33) | Unavailable | Resupply TBD | Demand increase for the drug |
| Injection, 10 mg/1 mL (NDC 16729-295-31) | Unavailable | Temporarily discontinued | Discontinuation of the manufacture of the drug |
Eugia US LLC (Revised 01/24/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01) | Currently on backorder next shipment Jan | Intermittent availability expected | Demand increase for the drug |
| Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01) | Currently on backorder next shipment Jan | Intermittent availability expected | Demand increase for the drug |
Fresenius Kabi USA, LLC (Reverified 04/08/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Injection, 10 mg/1 mL (NDC 63323-172-60) | Available | Check wholesaler for inventory |
Gland Pharma Limited (Revised 03/15/2024)
Company Contact Information:
Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270
Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01) | Available | Distributed by BPI Labs, LLC | |
| Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01) | Available | Distributed by BPI Labs, LLC | |
| Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01) | Available | Distributed by BPI Labs, LLC | |
| Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01) | Available | Distributed by BPI Labs, LLC |
Hospira, Inc., a Pfizer Company (Revised 02/27/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Injection, 10 mg/1 mL (NDC 61703-339-18) | Limited Availability, 1Q 2024 | Demand increase for the drug | |
| Injection, 10 mg/1 mL (NDC 61703-360-18) | Available | ||
| Injection, 10 mg/1 mL (NDC 61703-339-22) | Available | ||
| Injection, 10 mg/1 mL (NDC 61703-150-05) | Available | ||
| Injection, 10 mg/1 mL (NDC 61703-339-50) | Limited Availability, 1Q 2024 | Demand increase for the drug | |
| Injection, 10 mg/1 mL (NDC 61703-262-05) | Limited Availability, 1Q 2024 | Demand increase for the drug | |
| Injection, 10 mg/1 mL (NDC 61703-339-56) | Limited Availability, 1Q 2024 | Demand increase for the drug | |
| Injection, 10 mg/1 mL (NDC 61703-600-05) | Limited Availability, 3Q 2024 | Demand increase for the drug |
Ingenus Pharmaceuticals LLC (Revised 03/04/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Injection, 600 mg/60 mL (NDC 50742-448-60) | Available | For any other information, please contact the Ingenus Customer Service team at 866-321-5031. | |
| Injection, 450 mg/45 mL (NDC 50742-447-45) | Available | For any other information, please contact the Ingenus Customer Service team at 866-321-5031. |
Teva Pharmaceuticals USA, Inc. (Revised 02/06/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Injection, 10 mg/1 mL (NDC 0703-4239-01) | Allocatng Existing Supplies, - | ||
| Injection, 10 mg/1 mL (NDC 0703-4244-01) | Available | ||
| Injection, 10 mg/1 mL (NDC 0703-4246-01) | Allocating Existing Supplies | ||
| Injection, 10 mg/1 mL (NDC 0703-4248-01) | Unavailable, Recovery Estimated February TBD | Demand increase for the drug |
Teyro Labs (Reverified 04/02/2024)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Injection, 10 mg/1 mL (NDC 60505-6282-1) | Available | Wholesaler & Distributor through Marketing partner (Apotex Inc.) | |
| Injection, 10 mg/1 mL (NDC 60505-6282-3) | Available | Wholesaler & Distributor through Marketing partner (Apotex Inc.) | |
| Injection, 10 mg/1 mL (NDC 60505-6282-6) | Available | Wholesaler & Distributor through Marketing partner (Apotex Inc.) |